Targeted Molecular Therapeutics for Parkinson's Disease: A Role for Antisense Oligonucleotides?

Mov Disord. 2022 Nov;37(11):2184-2190. doi: 10.1002/mds.29201. Epub 2022 Aug 29.

Dunhui Li^{1

2

3}, Frank L Mastaglia^{1

2}, Wai Yan Yau¹, Shengdi Chen⁴, Steve D Wilton^{1

2}, Patrick A Akkari^{1

2

5}

¹ Perron Institute for Neurological and Translational Science, The University of Western Australia, Nedlands, Australia.
² Centre for Molecular Medicine and Innovative Therapeutics, Murdoch University, Murdoch, Australia.
³ College of Nursing and Health, Zhengzhou University, Zhengzhou, China.
⁴ Department of Neurology and Institute of Neurology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
⁵ Department of Neurology, Duke University, Durham, North Carolina, USA.

No abstract available

Publication types